These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 15711040)

  • 21. Do clinical outcomes in chronic hemodialysis depend on the choice of a dialyzer?
    Ward RA
    Semin Dial; 2011; 24(1):65-71. PubMed ID: 21323999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research on dialyzers with improved biocompatibility.
    van der Steen A
    Clin Nephrol; 1986; 26 Suppl 1():S39-42. PubMed ID: 3829466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes in the beta 2-microglobulin level during hemodialysis].
    Nikitinskaia LP; Stetsiuk EA; Iarmolinskiĭ IS; Barinov AV; Kon'kova TA
    Urol Nefrol (Mosk); 1990; (5):29-31. PubMed ID: 2264202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assembly of terminal SC5b-9 complement complexes: a new index of blood-membrane interaction.
    Schaefer RM; Rauterberg EW; Deppisch R; Vienken J
    Miner Electrolyte Metab; 1990; 16(1):73-6. PubMed ID: 2325595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma pentraxin-3 as a marker of bioincompatibility in hemodialysis patients.
    Oldani S; Finazzi S; Bottazzi B; Garlanda C; Baldassarre E; Valaperta S; Cuccovillo I; Albini M; Child M; Montanelli A; Graziani G; Badalamenti S
    J Nephrol; 2012; 25(1):120-6. PubMed ID: 21725917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biocompatibility study based on differential sequestration kinetics of CD14+CD16+ blood monocyte subsets with different dialyzers.
    Griveas I; Visvardis G; Sakellariou G; Passadakis P; Thodis I; Vargemezis V; Pavlitou A; Fleva A
    Ren Fail; 2006; 28(6):493-9. PubMed ID: 16928619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [C-reactive protein (CRP) as a marker of of hemodialysis biocompatibility].
    Szepietowski T; Krajewska M
    Polim Med; 1997; 27(1-2):47-59. PubMed ID: 9380601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of dialyzer compatibility by reduction of membrane surface area.
    Schaefer RM; Rautenberg W; Neumann S; Heidland A; Hörl WH
    Clin Nephrol; 1986; 26 Suppl 1():S35-8. PubMed ID: 3644705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-reactive protein in patients on chronic hemodialysis with different techniques and different membranes.
    Panichi V; Rizza GM; Taccola D; Paoletti S; Mantuano E; Migliori M; Frangioni S; Filippi C; Carpi A
    Biomed Pharmacother; 2006 Jan; 60(1):14-7. PubMed ID: 16330177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Factors which influence phosphorus removal in hemodialysis].
    Gallar P; Ortiz M; Ortega O; Rodríguez I; Seijas V; Carreño A; Oliet A; Vigil A
    Nefrologia; 2007; 27(1):46-52. PubMed ID: 17402879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of inflammation on anti-oxidative effects of vitamin E-coated membrane dialyzer in patients on chronic hemodialysis.
    Kirmizis D; Papagianni A; Efstratiadis G; Memmos D
    Hemodial Int; 2014 Oct; 18(4):751-7. PubMed ID: 24641709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biocompatibility and permeability of dialyzer membranes do not affect anemia, erythropoietin dosage or mortality in japanese patients on chronic non-reuse hemodialysis: a prospective cohort study from the J-DOPPS II study.
    Yokoyama H; Kawaguchi T; Wada T; Takahashi Y; Higashi T; Yamazaki S; Fukuhara S; Akiba T; Akizawa T; Asano Y; Kurokawa K; Saito A;
    Nephron Clin Pract; 2008; 109(2):c100-8. PubMed ID: 18596379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis.
    den Hoedt CH; Bots ML; Grooteman MP; van der Weerd NC; Mazairac AH; Penne EL; Levesque R; ter Wee PM; Nubé MJ; Blankestijn PJ; van den Dorpel MA;
    Kidney Int; 2014 Aug; 86(2):423-32. PubMed ID: 24552852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Reprocessing of capillary dialyzers].
    Stetsiuk EA; Iarmolinskiĭ IS; Ponomareva VIu; Makhlin NV
    Urol Nefrol (Mosk); 1989; (1):55-9. PubMed ID: 2718285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Membrane biocompatibility does not affect whole body protein metabolism during dialysis.
    Veeneman JM; Kingma HA; Stellaard F; de Jong PE; Reijngoud DJ; Huisman RM
    Blood Purif; 2005; 23(3):211-8. PubMed ID: 15809504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The study of IL-1 beta, TNF-alpha, IL-6 gene expression and plasma levels on hemodialysis before and after dialyzer reuse.
    Qian J; Yu Z; Dai H; Huang P; Zhang Q; Cheng F; Chen S
    Chin Med J (Engl); 1997 Jul; 110(7):508-11. PubMed ID: 9594206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum growth factors in hemodialyzed patients.
    Paczek L; Gomółka M; Niemczyk S; Bartłomiejczyk I; Gerwatowska D; Sebekova K; Heidland A
    Artif Organs; 2004 Mar; 28(3):314-6. PubMed ID: 15046632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Automatic re-utilization of capillary dialysis].
    Szepietowski T; Uzar J
    Polim Med; 1989; 19(3-4):107-18. PubMed ID: 2641400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of re-utilization of cuprophan capillary dialysers with different liquids on their biocompatibility and effectiveness of elimination].
    Orłowski A; Szepietowski T
    Polim Med; 1992; 22(1-2):59-72. PubMed ID: 1461837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biocompatibility of the dialysis membrane.
    Takemoto Y; Naganuma T; Yoshimura R
    Contrib Nephrol; 2011; 168():139-145. PubMed ID: 20938134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.